Ajinomoto acquires Japanese risedronate rights
This article was originally published in Scrip
Executive Summary
The diversified Japanese company Ajinomoto is paying $210 million to Procter & Gamble for the full rights in its home market to the osteoporosis drug risedronate, for which it is already the local licensee.